• Je něco špatně v tomto záznamu ?

Double-blind randomized multicenter study comparing the efficacy and safety of 10-day to 5-day terlipressin treatment of bleeding esophageal varices

R. Brůha, Z. Mareček, V. Procházka, J. Lata, J. Špičák, J. Ehrmann, R. Kroupa, J. Petrtýl, J. Dolina, P. Taimr, P. Drastich, P. Urbánek, D. Vrzalová

. 2009 ; 56 (90) : 390-394.

Jazyk angličtina Země Řecko

Typ dokumentu multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc11019590

Grantová podpora
NR9406 MZ0 CEP - Centrální evidence projektů

BACKGROUND/AIMS: The aim of the study was to compare the efficacy and safety of 5-day terlipressin treatment of bleeding esophageal varices to 10-day treatment period. METHODOLOGY: Of 25 patients with variceal bleeding, 15 were randomized to receive terlipressin for day 1-5 and placebo for day 6-10 (Group A), and 10 to receive terlipressin for day 1-10 (Group B). RESULTS: The bleeding was stopped in 24 patients (96%). Rebleeding till day 42 was observed in 9 (36%) patients (5 in group A, 4 in group B, ns). 2 patients died in group B (due to rebleeding till day 5) and one in group A (rebleeding between day 5-10). Transfusion needs were lower in group B (2.7 +/- 2.6TU compared to 4.13 +/- 5.8 TU in group A, ns). Serious AE leading to treatment discontinuation were observed in 1 patient in group A (peripheral ischemia) and none in B, non-significant AE in 3 patients in group A (hypertension), and in 3 in group B (hypertension, hyponatremia, epiparoxysm). CONCLUSIONS: Prolonged treatment with terlipressin did not prove significant decrease of mortality or bleeding recurrence; lower rebleeding rate after day 5 and tendency towards lower transfusion requirements were observed. Prolonged treatment had no influence on AE rate.

000      
03220naa 2200517 a 4500
001      
bmc11019590
003      
CZ-PrNML
005      
20221005134614.0
008      
110714s2009 gr e eng||
009      
AR
035    __
$a (PubMed)19579605
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Brůha, Radan, $d 1964- $7 xx0031692
245    10
$a Double-blind randomized multicenter study comparing the efficacy and safety of 10-day to 5-day terlipressin treatment of bleeding esophageal varices / $c R. Brůha, Z. Mareček, V. Procházka, J. Lata, J. Špičák, J. Ehrmann, R. Kroupa, J. Petrtýl, J. Dolina, P. Taimr, P. Drastich, P. Urbánek, D. Vrzalová
314    __
$a Charles University in Prague, First Faculty of Medicine, 4th Department of Internal Medicine Prague, Czech Republic. bruha@cesnet.cz
520    9_
$a BACKGROUND/AIMS: The aim of the study was to compare the efficacy and safety of 5-day terlipressin treatment of bleeding esophageal varices to 10-day treatment period. METHODOLOGY: Of 25 patients with variceal bleeding, 15 were randomized to receive terlipressin for day 1-5 and placebo for day 6-10 (Group A), and 10 to receive terlipressin for day 1-10 (Group B). RESULTS: The bleeding was stopped in 24 patients (96%). Rebleeding till day 42 was observed in 9 (36%) patients (5 in group A, 4 in group B, ns). 2 patients died in group B (due to rebleeding till day 5) and one in group A (rebleeding between day 5-10). Transfusion needs were lower in group B (2.7 +/- 2.6TU compared to 4.13 +/- 5.8 TU in group A, ns). Serious AE leading to treatment discontinuation were observed in 1 patient in group A (peripheral ischemia) and none in B, non-significant AE in 3 patients in group A (hypertension), and in 3 in group B (hypertension, hyponatremia, epiparoxysm). CONCLUSIONS: Prolonged treatment with terlipressin did not prove significant decrease of mortality or bleeding recurrence; lower rebleeding rate after day 5 and tendency towards lower transfusion requirements were observed. Prolonged treatment had no influence on AE rate.
590    __
$a bohemika - dle Pubmed
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ezofageální a žaludeční varixy $x farmakoterapie $7 D004932
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lypresin $x analogy a deriváty $x aplikace a dávkování $x terapeutické užití $7 D008236
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a bezpečnost $7 D012449
650    _2
$a neparametrická statistika $7 D018709
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vazokonstriktory $x aplikace a dávkování $x terapeutické užití $7 D014662
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mareček, Zdeněk, $d 1938- $7 nlk19990073533
700    1_
$a Procházka, Vlastimil, $d 1958- $7 nlk20030127455
700    1_
$a Lata, Jan, $7 mzk2005282575 $d 1953-
700    1_
$a Špičák, Julius, $d 1952- $7 jn20000919536
700    1_
$a Ehrmann, Jiří, $d 1940- $7 xx0000871
700    1_
$a Kroupa, Radek $7 xx0079790
700    1_
$a Petrtýl, Jaromír, $7 xx0089233 $d 1958-
700    1_
$a Dolina, Jiří $7 xx0017693
700    1_
$a Taimr, Pavel, $7 xx0051626 $d 1964-
700    1_
$a Drastich, Pavel, $7 xx0058265 $d 1963-
700    1_
$a Urbánek, Petr, $d 1969- $7 jn20001103565
700    1_
$a Vrzalová, Drahomíra. $7 xx0225184
773    0_
$t Hepato-Gastroenterology $w MED00002025 $g Roč. 56, č. 90 (2009), s. 390-394 $x 0172-6390
910    __
$a ABA008 $b x $y 2 $z 0
990    __
$a 20110715114339 $b ABA008
991    __
$a 20221005134609 $b ABA008
999    __
$a ok $b bmc $g 864467 $s 729468
BAS    __
$a 3
BMC    __
$a 2009 $x MED00002025 $b 56 $c 90 $d 390-394 $i 0172-6390 $m Hepato-gastroenterology $n Hepatogastroenterology
GRA    __
$a NR9406 $p MZ0
LZP    __
$a 2011-3B09/Bjvme

Najít záznam

Citační ukazatele

Možnosti archivace